• Pharmacy
Vizient Publishes White Paper on Maximizing Pharmacy Performance
IRVING, Texas--(BUSINESS WIRE)--Pharmacy leaders and their health systems are at a crossroads. Moving forward, they can continue traditional approaches to pharmacy operations or adopt emerging perspectives that improve performance. To help drive informed d...
  • Pharmacy
Vizient Releases New Drug Price Forecast for 2018-2019: Price Increases Slow, But Challenges Remain
IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. has released its January 2018 Drug Price Forecast and estimates that for pharmaceutical purchases made from July 1, 2018 to June 30, 2019, health systems can expect a 7.35 percent increase. An executive summary...
  • Pharmacy
Vizient Drug Price Forecast Projects 4.28 Percent Increase for 2019-2020
IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. released today its January 2019 Drug Price Forecast projecting health systems, including inpatient and non-acute environments, can expect a 4.28 percent increase for pharmaceutical purchases made from July 1, 2...
  • Pharmacy
Vizient to Present on Pharmaceutical Traceability at Healthcare Distribution Alliance’s Distribution Management Conference and Expo
IRVING, Texas--(BUSINESS WIRE)--Vizient announces that it will be presenting at the HDA Distribution Management Conference and Expo, being held March 10-13 at the JW Marriott Desert Springs in Palm Desert, Calif. During the event, Katrina Harper, PharmD, M...
  • Company
  • Pharmacy
Vizient Endorses Legislation to Support Competition and Biosimilar Adoption to Lower Drug Prices
IRVING, Texas--(BUSINESS WIRE)--Vizient today announced that it has endorsed two more bills aimed at reducing drug prices by taking steps to support competition in the prescription drug marketplace. First, Vizient endorsed the Fair Access for Safe and Time...
  • Pharmacy
Vizient to Participate in Becker’s Hospital Review’s Webinar on Pharmacy Trends
IRVING, Texas--(BUSINESS WIRE)--Vizient announces its participation in the panel discussion for the upcoming webinar, “What’s Trending in Hospital Pharmacy in 2019,” hosted by Becker’s Hospital Review. The webinar is scheduled from noon to 1 p.m. CDT Wedne...
  • Pharmacy
Vizient to Present at FDA Hearing on the Future of Insulin Biosimilars
IRVING, Texas--(BUSINESS WIRE)--Vizient Inc. announces that Steven Lucio, PharmD, BCPS, vice president, pharmacy solutions, will present on behalf of the company and its member hospitals at the Food and Drug Administration’s (FDA) public hearing “The Futur...
  • Pharmacy
Vizient to Participate in B. Braun’s “Be A Part of the Solution – Alleviating IV Fluid Shortages” Panel
WASHINGTON--(BUSINESS WIRE)--Vizient Inc.’s Senior Vice President for sourcing operations, David Gillan, today joins health care leaders from across the nation to discuss the needs and challenges caused by recent intravenous (IV) fluid shortages as well as...
  • Pharmacy
New Vizient Survey Finds Drug Shortages Cost Hospitals Just Under $360M Annually in Labor Expenses
IRVING, Texas--(BUSINESS WIRE)--Drug shortages are challenging pharmacy teams in hospitals across the United States. A new survey from Vizient, Inc. finds that, on average, hospitals in the U.S. dedicate more than 8.6 million hours of additional labor hour...
  • Pharmacy
Vizient Drug Price Forecast Projects 4.57 Percent Increase in Hospital Drug Spending for 2020
IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. has released its July 2019 Drug Price Forecast projecting health systems, including inpatient and non-acute environments, can expect a 4.57 percent increase for pharmaceutical purchases made from Jan. 1, 2020 t...
  • Pharmacy
Vizient Identifies Essential Medications in Hospitals and Highlights Fragility of the Supply Chain
IRVING, Texas--(essential medicationswhose absence may threaten hospitals’ ability to provide immediate and high quality patient care, including 77 acute and chronic life-saving drugs that have no alternatives in the event of a supply disruption.
  • Company
  • Pharmacy
Vizient Comments Support FDA’s Efforts to Expedite Biosimilar Insulin Development
IRVING, Texas--(commentsto the Food and Drug Administration (FDA) in response to its draft guidance, “Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.”
  • Pharmacy
New Vizient Drug Price Forecast Estimates 3.59% Increase for 2020-2021
Vizient releases its Winter 2020 Drug Price Forecast projecting a 3.59% increase in drug expenditures for hospitals from July 1, 2020 to June 30, 2021
  • Pharmacy
Vizient Experts to Participate at HSCA National Pharmacy Forum 2020
Vizient will participate at the Healthcare Supply Chain Association National Pharmacy Forum 2020 Feb. 3-5 in Scottsdale, Arizona.
  • Pharmacy
Vizient Analysis Shows Prices for Existing Drugs Spike After Regulatory Approval, Potentially Increasing Spending by $29 Billion
Analysis by Vizient projects a $29B increase in cost to US healthcare from existing drugs that spike in price after gaining regulatory approval.
  • Company
  • Pharmacy
Vizient to Present at FDA/FTC Workshop on a Competitive Marketplace for Biosimilars
Vizient, Inc. will participate in today’s FDA/FTC Workshop on a Competitive Marketplace for Biosimilars.
  • Company
  • Pharmacy
Vizient Offers Recommendation to Coronavirus Task Force and FDA to Improve Hospitals’ Access to Chloroquine and Hydroxychloroquine as Suppliers Unable to Keep Up with 6,842% and 2,196% Increases in Orders
Vizient offers recommendations to the White House Coronavirus Task Force and FDA to improve hospital access to chloroquine and hydroxychloroquine.
  • Company
  • Pharmacy
Vizient Applauds FDA’s Temporary Policy Enabling Compounding Pharmacies to Produce Essential Medications Required for Hospitalized Patients during COVID-19 Emergency
Vizient applauds the decision by the FDA to allow compounding pharmacies to produce a range of drugs necessary to treat COVID-19 patients.
  • Pharmacy
Vizient’s Novaplus Enhanced Supply Program Enabled Access to 676,000 Additional Units of Propofol as COVID-19 Cases Surged
A novel Vizient supply program resulted in the availability of an additional 676,000 units of the sedative propofol, used to intubate COVID patients.
  • Pharmacy
Vizient Essential Medications List Updated with 12 Additional Drugs
Vizient adds 12 drugs to its essential medications list; drugs whose absence would threaten hospitals’ ability to provide timely, quality care.
  • Pharmacy
Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications
Vizient announces an agreement with Pfizer to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program.
  • Pharmacy
Vizient Data Show 610% Increase in Demand for Dexamethasone after Study Shows Effectiveness for Patients Severely Ill with COVID-19
Vizient shares data showing a 610% increase in demand by its members for dexamethasone in the week since study linking treatment for COVID patients.
  • Pharmacy
Vizient Provides Feedback to Government Agencies on Drug Compounding and Improving Competition for Generics and Biosimilars
Vizient offers insights to FDA and USPTO on actions to increase access to compounded drugs and improve opportunities for new generics and biosimilars.